[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100482830":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":12,"locations":20,"responsibleParty":54,"collaborators":56,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":68,"sex":74,"minAge":75,"maxAge":7,"enrollmentInfo":76,"targetDuration":7,"studyType":79,"phases":7,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":23,"whyStopped":7,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"University of California, San Francisco","OTHER",null,[9],{"name":10,"affiliation":5,"role":11},"Laura Koth","PRINCIPAL_INVESTIGATOR",[13,17],{"name":10,"role":14,"phone":15,"phoneExt":7,"email":16},"CONTACT","4155144369","laura.koth@ucsf.edu",{"name":18,"role":14,"phone":7,"phoneExt":7,"email":19},"Jessica Cardenas","jessica.cardenas@ucsf.edu",[21,39],{"facility":22,"status":23,"city":24,"state":25,"zip":26,"country":27,"countryCode":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":35},"University of Maryland","RECRUITING","Baltimore","Maryland","21201","United States","US",{"type":30,"coordinates":31},"Point",[32,33],-76.61219,39.29038,{"lat":33,"lon":32},[36],{"name":37,"role":14,"phone":7,"phoneExt":7,"email":38},"Wonder P Drake, MD","wdrake@som.umaryland.edu",{"facility":40,"status":23,"city":41,"state":42,"zip":43,"country":27,"countryCode":28,"cosmosGeoPoint":44,"geoPoint":48,"contacts":49},"UT Southwestern","Dallas","Texas","75390",{"type":30,"coordinates":45},[46,47],-96.80667,32.78306,{"lat":47,"lon":46},[50],{"name":51,"role":14,"phone":52,"phoneExt":7,"email":53},"Fabiola Gianella","214-648-7875","Fabiola.Gianella@UTsouthwestern.edu",{"type":55,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[57,59,61,63],{"name":58,"class":6},"Vanderbilt University Medical Center",{"name":60,"class":6},"University of Texas, Southwestern Medical Center at Dallas",{"name":62,"class":6},"Wayne State University",{"name":64,"class":65},"National Heart, Lung, and Blood Institute (NHLBI)","NIH","100482830","risk-indicators-of-sarcoidosis-evolution-unified-protocol-100482830",false,"NCT05567133","Risk Indicators of Sarcoidosis Evolution-Unified Protocol","Development of Clinical Prediction Models for Pulmonary Outcomes in Sarcoidosis","RISE-UP","Inclusion Criteria:\n\n1. Adults with a diagnosis of sarcoidosis over the age of 18\n2. Case definition: we will follow the 1999 statement on sarcoidosis published by the American Thoracic Society for diagnosis which includes tissue biopsy confirmation and exclusion of alternative diagnoses including beryllium sensitization\u002Fchronic beryllium disease, mycobacterial, viral, and\u002For fungal infection\n\nExclusion Criteria:\n\n1. Inability to tolerate study procedures as determined by the investigator\n2. Pregnant or breastfeeding\n3. Concurrent medical diagnoses that would influence the expression of biomarkers will be considered an exclusion criterion. This includes diseases such as common variable immunodeficiency, HIV infection, or autoimmune diseases\n4. Concurrent interstitial lung diseases such as hypersensitivity pneumonitis or idiopathic pulmonary fibrosis\n5. Hematocrit (Packed Cell Volume) \\\u003C 25%","ALL","19 Years",{"count":77,"type":78},200,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to develop prediction models that can prognosticate patients with sarcoidosis using clinical data and blood markers that can be obtained during a clinic visit.",[82],"Sarcoidosis, Pulmonary",[84],"sarcoid, lung, immune","2026-01-06",{"date":87,"type":88},"2026-01-08","ACTUAL",{"date":90,"type":88},"2023-01-10",{"date":92,"type":78},"2030-03-30",{"name":5,"class":6},2]